Common Contracts
48 similar Placement Agency Agreement contracts by MusclePharm Corp, BSD Medical Corp, LIGHTBRIDGE Corp, others
INVENTERGY GLOBAL, INC. PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • October 12th, 2016 • Inventergy Global, Inc. • Telephone communications (no radiotelephone) • New York
Inventergy Global, Inc., a Delaware Corporation (the “Company”), proposes, subject to the terms and conditions herein, to issue and sell up to an aggregate of 6,000,000 shares (the “Shares”) of Common Stock of the Company, par value $0.001 per share (the “Common Stock”), warrants to purchase up to an aggregate of 6,000,000 shares of Common Stock (the “Warrants”), and up to an aggregate of 6,000,000 shares of Common Stock issuable from time to time upon exercise of the Warrants (the “Warrant Shares”) to certain investors (each an “Investor” and, collectively, the “Investors”), in an offering under its registration statement on Form S-1 (Registration No. 333-211211). We are offering one Share together with one Warrant (the Shares and the Warrants, together, the “Securities”) with each whole Warrant exercisable for one Warrant Share. The Securities are more fully described in the Prospectus (as defined below). The Company desires to engage Chardan Capital Markets, LLC (“Chardan”) in conne
INVENTERGY GLOBAL, INC. PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • September 9th, 2016 • Inventergy Global, Inc. • Telephone communications (no radiotelephone) • New York
Inventergy Global, Inc., a Delaware Corporation (the “Company”), proposes, subject to the terms and conditions herein, to issue and sell up to an aggregate of 5,000,000 shares (the “Shares”) of Common Stock of the Company, par value $0.001 per share (the “Common Stock”), warrants to purchase up to an aggregate of 5,000,000 shares of Common Stock (the “Warrants”), and up to an aggregate of 5,000,000 shares of Common Stock issuable from time to time upon exercise of the Warrants (the “Warrant Shares”) to certain investors (each an “Investor” and, collectively, the “Investors”), in an offering under its registration statement on Form S-1 (Registration No. 333-211211). We are offering one Share together with one Warrant (the Shares and the Warrants, together, the “Securities”) with each whole Warrant exercisable for one Warrant Share. The Securities are more fully described in the Prospectus (as defined below). The Company desires to engage Chardan Capital Markets, LLC (“Chardan”) in conne
NORTHWEST BIOTHERAPEUTICS, INC. PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • July 11th, 2016 • Northwest Biotherapeutics Inc • Pharmaceutical preparations • New York
2,145,000 Shares Accelerize Inc. Common Stock, par value $0.001 per share PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • August 14th, 2015 • Accelerize Inc. • Services-business services, nec • New York
Accelerize Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this Placement Agency Agreement (this “Agreement”) and the Securities Purchase Agreement in a form mutually agreed upon by the Company and the Placement Agent (the “Purchase Agreement”) entered into with the investors identified therein (each, an “Investor” and collectively, the “Investors”), to issue and sell up to an aggregate of 2,145,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The Company hereby confirms its agreement with Craig-Hallum Capital Group LLC (“Craig-Hallum” or the “Placement Agent”) as set forth below. The Shares are more fully described in the Prospectus (as defined below).
PLACEMENT AGENCY AGREEMENT 2,878,516 Shares of Common Stock Warrants to purchase 2,734,590 Shares of Common StockPlacement Agency Agreement • November 18th, 2014 • LIGHTBRIDGE Corp • Services-management consulting services • New York
Lightbridge Corporation, a Nevada corporation (the “Company”), proposes, subject to the terms and conditions herein, to issue and sell an aggregate of up to 2,878,516 units, each consisting of (i) one share (the “Shares”) of its common stock, $0.001 par value per share (the “Common Stock”), and (ii) a warrant to purchase 0.95 shares of Common Stock (the “Warrants”), to certain investors (each an “Investor” and collectively the “Investors”), in an offering under its registration statement on Form S-3 (Registration No. 333-187659). The shares of Common Stock issuable upon exercise of the Warrants are hereinafter referred to as the “Warrant Shares” and the Shares, the Warrants and the Warrant Shares are hereinafter referred to as the “Securities.” The Securities are more fully described in the Prospectus (as defined in Section 2(a)(iii) hereof). The Company desires to engage William Blair & Company, L.L.C. as the Company’s exclusive placement agent (in such capacity, the “Placement Agent”
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • October 1st, 2014 • Assembly Biosciences, Inc. • Pharmaceutical preparations • New York
FORM OF PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • August 6th, 2014 • VistaGen Therapeutics, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • July 30th, 2014 • CYREN Ltd. • Communications services, nec • New York
FORM OF PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • July 28th, 2014 • VistaGen Therapeutics, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 26th, 2013 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations • New York
The undersigned, Oramed Pharmaceuticals Inc., a corporation formed under the laws of the State of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Oramed Pharmaceuticals, Inc., the "Company"), hereby confirms its agreement (this "Agreement") with Aegis Capital Corp as placement agent (the "Placement Agent") as follows:
DELCATH SYSTEMS, INC. PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • October 28th, 2013 • Delcath Systems, Inc. • Surgical & medical instruments & apparatus • New York
Delcath Systems, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions herein, to issue and sell an aggregate of up to (i) 20,960,000 shares (the “Shares”) of its common stock, par value $0.01 per share (the “Common Stock”), and (ii) 9,432,000 warrants to purchase shares of Common Stock (the “Warrants”) to certain investors (each an “Investor” and, collectively, the “Investors”), in an offering under its registration statement on Form S-3 (Registration No. 333-183675). The shares of Common Stock issuable upon exercise of the Warrants are hereinafter referred to as the “Warrant Shares” and the Shares, the Warrants and the Warrant Shares are hereinafter referred to as the “Securities”. The Securities are more fully described in the Prospectus (as defined below). The Company desires to engage Roth Capital Partners, LLC (“Roth”) in connection with such issuance and sale of the Securities.
DELCATH SYSTEMS, INC. FORM OF PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • October 23rd, 2013 • Delcath Systems, Inc. • Surgical & medical instruments & apparatus • New York
Delcath Systems, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions herein, to issue and sell an aggregate of up to (i) [ ] shares (the “Shares”) of its common stock, par value $0.01 per share (the “Common Stock”), and (ii) [ ] warrants to purchase shares of Common Stock (the “Warrants”) to certain investors (each an “Investor” and, collectively, the “Investors”), in an offering under its registration statement on Form S-3 (Registration No. 333-183675). The shares of Common Stock issuable upon exercise of the Warrants are hereinafter referred to as the “Warrant Shares” and the Shares, the Warrants and the Warrant Shares are hereinafter referred to as the “Securities”. The Securities are more fully described in the Prospectus (as defined below). The Company desires to engage Roth Capital Partners, LLC (“Roth”) in connection with such issuance and sale of the Securities.
PLACEMENT AGENCY AGREEMENT 2,500,000 Shares of Common Stock Warrants to purchase 1,250,000 Shares of Common StockPlacement Agency Agreement • October 22nd, 2013 • LIGHTBRIDGE Corp • Services-management consulting services • New York
Lightbridge Corporation, a Nevada corporation (the “Company”), proposes, subject to the terms and conditions herein, to issue and sell an aggregate of up to 2,500,000 units, each consisting of (i) one share (the “Shares”) of its common stock, $0.001 par value per share (the “Common Stock”), and (ii) a warrant to purchase 0.5 shares of Common Stock (the “Warrants”), to certain investors (each an “Investor” and collectively the “Investors”), in an offering under its registration statement on Form S-3 (Registration No. 333-187659). The shares of Common Stock issuable upon exercise of the Warrants are hereinafter referred to as the “Warrant Shares” and the Shares, the Warrants and the Warrant Shares are hereinafter referred to as the “Securities.” The Securities are more fully described in the Prospectus (as defined in Section 2(a)(iii) hereof). The Company desires to engage William Blair & Company, L.L.C. as the Company’s exclusive placement agent (in such capacity, the “Placement Agent”)
PLACEMENT AGENCY AGREEMENT April 9, 2013Placement Agency Agreement • April 9th, 2013 • BSD Medical Corp • Electromedical & electrotherapeutic apparatus • New York
AUGME TECHNOLOGIES, INC. PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • January 30th, 2013 • Augme Technologies, Inc. • Communications equipment, nec • New York
Augme Technologies, Inc., a Delaware Corporation (the “Company”), proposes, subject to the terms and conditions herein, to issue and sell up to an aggregate of 13,469,661 shares (the “Shares”) of Common Stock of the Company, par value$0.0001 per share (the “Common Stock”), warrants to purchase up to an aggregate of 6,734,831 shares of Common Stock (the “Warrants”), and up to an aggregate of 6,734,831 shares of Common Stock issuable from time to time upon exercise of the Warrants (the “Warrant Shares”) to certain investors (each an “Investor” and, collectively, the “Investors”), in an offering under its registration statement on Form S-3 (Registration No. 333-175191). We are offering the Shares and Warrants in units (each, a “Unit”), with each Unit consisting of one Share together with one-half of one Warrant and each whole Warrant exercisable for one Warrant Share. The Units are more fully described in the Prospectus (as defined below). The Company desires to engage Roth Capital Partne
PLACEMENT AGENCY AGREEMENT January 16, 2013Placement Agency Agreement • January 23rd, 2013 • MusclePharm Corp • Pharmaceutical preparations • Colorado
FORM OF PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • January 8th, 2013 • MusclePharm Corp • Pharmaceutical preparations • Colorado
MusclePharm Corporation, a Nevada corporation (the “Company”), proposes, subject to the terms and conditions herein, to issue and sell an aggregate of up to [•] shares (the “Shares”) of its Series D Convertible preferred stock, $0.001 par value per share (the “Series D Preferred”), which are convertible into shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), to certain investors in a registered offering. The terms of the Series D Preferred will be set forth in a certificate of designation (the “Certificate of Designation”) to be filed by the Company with the Secretary of State of the State of Nevada. The Company desires to engage GVC Capital LLC (the “Placement Agent”) as an exclusive placement agent in connection with such issuance and sale of the Shares.
FORM OF PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 31st, 2012 • MusclePharm Corp • Pharmaceutical preparations • New York
FORM OF PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 26th, 2012 • MusclePharm Corp • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 19th, 2012 • Superconductor Technologies Inc • Radio & tv broadcasting & communications equipment • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • September 19th, 2012 • Neuralstem, Inc. • Biological products, (no disgnostic substances) • New York
PLACEMENT AGENCY AGREEMENT May 24, 2012Placement Agency Agreement • May 25th, 2012 • Rosetta Genomics Ltd. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENT May 16, 2012Placement Agency Agreement • May 17th, 2012 • Rosetta Genomics Ltd. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENT April 12, 2012Placement Agency Agreement • April 16th, 2012 • Rosetta Genomics Ltd. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENT April 16, 2012Placement Agency Agreement • April 16th, 2012 • Lucas Energy, Inc. • Crude petroleum & natural gas • New York
PLACEMENT AGENCY AGREEMENT January 31, 2012Placement Agency Agreement • February 1st, 2012 • ChromaDex Corp. • Medicinal chemicals & botanical products • New York
PLACEMENT AGENCY AGREEMENT December 8, 2011Placement Agency Agreement • December 9th, 2011 • Oxygen Biotherapeutics, Inc. • Services-commercial physical & biological research • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • September 2nd, 2011 • Peregrine Pharmaceuticals Inc • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENT April 18, 2011Placement Agency Agreement • April 18th, 2011 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
PLACEMENT AGENCY AGREEMENT January 27, 2011Placement Agency Agreement • January 28th, 2011 • Athersys, Inc / New • Pharmaceutical preparations • New York
Athersys, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions herein, to issue and sell an aggregate of up to (i) an aggregate of 4,366,667 shares (the “Shares”) of its common stock, $0.001 par value per share (the “Common Stock”), and (ii) warrants to purchase up to an additional 1,310,000 shares of Common Stock (the “Warrants”), to certain investors (each an “Investor” and collectively the “Investors”), in an offering under its registration statement on Form S-3 (Registration No. 333-164336). The shares of Common Stock issuable upon exercise of the Warrants are hereinafter referred to as the “Warrant Shares” and the Shares, the Warrants and the Warrant Shares are hereinafter referred to as the “Securities.” The Securities are more fully described in the Prospectus (as defined in Section 2(a)(iii) hereof). The Company desires to engage William Blair & Company, L.L.C. and First Analysis Securities Corporation in connection with such issuance and
PLACEMENT AGENCY AGREEMENT November 15, 2010Placement Agency Agreement • November 15th, 2010 • BSD Medical Corp • Electromedical & electrotherapeutic apparatus • New York
BIONOVO, INC. PLACEMENT AGENCY AGREEMENT October 1, 2010Placement Agency Agreement • October 4th, 2010 • Bionovo Inc • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENT August 19, 2010Placement Agency Agreement • August 19th, 2010 • BSD Medical Corp • Electromedical & electrotherapeutic apparatus • New York
PLACEMENT AGENCY AGREEMENT July 22, 2010Placement Agency Agreement • July 23rd, 2010 • LIGHTBRIDGE Corp • Services-management consulting services • New York
PLACEMENT AGENCY AGREEMENT May 4, 2010Placement Agency Agreement • May 4th, 2010 • Oxygen Biotherapeutics, Inc. • Services-commercial physical & biological research • New York
